60 stories tagged with #lilly, in publish-time order across the WeSearch catalog. Tag pages update as new stories ingest.
⌘ RSS feed for this tag → or search "Lilly"
STAT+: The loophole in Trump’s obesity drug deal with Eli Lilly and Novo Nordisk
The Trump administration's grand bargain with drugmakers isn't working out as planned.…
Forget Weight Loss: Eli Lilly's Real Upside Is As An AI Compounder
Eli Lilly is leveraging its exceptional cash flow to build an AI-native drug discovery and manufacturing platform. Read why LLY stock is a Buy.…
Boy, 14, charged with murder over death of teenager Lilly in Wales
Gwent police say accused will face court in Newport following arrest over discovery of teenage girl’s body in Duffryn Park area of Blaina A 14-year-old boy has been charged with mu…
STAT+: Democrats press White House on who got special access to Eli Lilly’s new obesity drug
The unusual access to an experimental drug has captured the attention of the American public as well.…
STAT+: Abridge inks deals with Nvidia and Lilly
Abridge announced new deals with Eli Lilly and Nvidia as it aims to gain an edge in a competitive market.…
STAT+: Pharmalittle: We’re reading about Lilly and Pfizer obesity drug data, Roche and J&J deals, and more
Lilly disclosed new data that provide more details on the safety and tolerability of its next-generation obesity drug retatrutide…
Prediction: Eli Lilly Will Be Worth More Than SpaceX in 2 Years
Lilly cuts Germany investment plan in half over healthcare reforms
Where Will Eli Lilly Stock be In 2028?
Eli Lilly is striking a $1.9 billion gene-editing deal to develop inherited kidney disease treatments
Eli Lilly signs $1.9B gene-editing deal with Ascidian Therapeutics
Eli Lilly's top dealmaker says don't be surprised to see more M&A that pushes Lilly into new areas
Eli Lilly's new top dealmaker explains how the company changed its approach to M&A now that it's the most valuable pharmaceutical company in the world.…
STAT+: Pharmalittle: We’re reading about a Lilly threat to 340B hospitals, Ebola vaccine funding, and more
Lilly gave hospitals participating in a federal drug discount program five days to submit claims data or it will stop the price breaks…
STAT+: Eli Lilly warns hospitals to submit claims data in the next five days or lose their 340B drug discounts
Eli Lilly has told more than 1,000 hospitals participating in the 340B drug discount program to submit claims data over the next five days — or lose price breaks.…
STAT+: A turning point for pancreatic cancer patients
Eli Lilly announces two China deals, Akeso's lung cancer bispecific payoff, and more biotech news from The Readout…
Name tweak could boost GLP-1 access for one in eight women suffering PMOS
Millions of women could soon have greater access to GLP-1 weight loss medications following the global effort to change the name of a hormonal condition that affects 1 in 8 women g…
Eli Lilly and Company (LLY): A Long Term Stock to Buy
Eli Lilly and Company (LLY) Presents at Bernstein 42nd Annual Strategic Decisions Conference Transcript
Eli Lilly and Company (LLY) Bernstein 42nd Annual Strategic Decisions Conference May 28, 2026 1:30 PM EDTCompany ParticipantsDaniel Skovronsky - Chief...…
CVS brings back coverage for Lilly's obesity drug Zepbound - Reuters
CVS brings back coverage for Lilly's obesity drug Zepbound Reuters…
Lilly’s GLP-1 medications will soon be covered by CVS, potentially opening access for millions of Americans
Healthy Returns: Eli Lilly makes a new push into vaccines – here’s what to know
The drugmaker announced it will buy three privately held vaccine makers in deals worth almost $4 billion combined.…
Lilly to buy three vaccine developers for nearly $4 billion in infectious disease push - Reuters
Comprehensive up-to-date news coverage, aggregated from sources all over the world by Google News.…
Eli Lilly to Buy 3 Vaccine Developers
STAT+: Pharmalittle: We’re reading about a Lilly gene therapy for cholesterol, three new Lilly deals, and more
Eli Lilly reported that a high dose of its gene-editing therapy reduced cholesterol levels by 62% in participants in a Phase 1 clinical trial…
Here’s What the Street is Saying About Eli Lilly and Company (LLY)
Eli Lilly stock edges higher as company plans nearly $4 billion in vaccine deals
The deals are part of Eli Lilly’s effort to expand into infectious disease research and development.…
Eli Lilly acquires three vaccine developers for $3.8 billion
STAT+: Eli Lilly to buy three small vaccine developers
Eli Lilly is acquiring three small vaccine developers, expanding its work in infectious diseases and giving the field a boost.…
Eli Lilly is acquiring three vaccine startups as it makes a push into infectious disease
Lilly to acquire three vaccine developers for nearly $4-billion
Drugmaker has been on acquisition spree as it expands beyond weight loss to other therapeutic areas…
Weight-Loss Pill Approval Highlights Important Role of PCPs
FDA approval of Eli Lilly’s weight-loss pill on April 1 shows the fast-changing landscape for weight loss, obesity medications.…
Leerink reiterates Eli Lilly stock rating on gene therapy progress
STAT+: Eli Lilly says Verve’s gene editor lowers cholesterol levels in early study
Eli Lilly said Monday that a high dose of its gene-editing therapy reduced cholesterol levels by 62% in participants in a clinical trial.…
CNBC Reports Strong Phase 3 Results for Eli Lilly’s Retatrutide
Eli Lilly (LLY) Announces Positive Phase 3 Results for Obesity Treatment Retatrutide
Trump Bought Stock in Eli Lilly as His Policies Gave the Drugmaker a Big Boost, Documents Show
Get our weekly newsletter, The Week in Brief, featuring a roundup of our original coverage, Fridays at 2 p.m. ET.…
Eli Lilly says its next gen obesity drug is more powerful than Zepbound and Wegovy
Eli Lilly announced clinical trial results for retatrutide, its next gen obesity drug. The drug helped study participants lose 70 lbs over 80 weeks, making it more powerful than Ze…
New obesity drug from Lilly delivers major weight loss
An investigational obesity drug from Eli Lilly cleared important end points in a late-stage trial, the company said Thursday, by helping patients lose up to 30 percent of their bod…
Eli Lilly (LLY) Sees Strong Growth Driven by Mounjaro Momentum and GLP-1 Demand, Barclays Remains Bullish
New Eli Lilly weight loss drug has dramatic effects in clinical trial
An experimental anti-obesity injection helped patients reach new levels of weight loss previously only achievable through bariatric surgery, according to new data from the pharmace…
A Next-Generation Drug Causes Dramatic Weight Loss, Eli Lilly Says
Retatrutide, an experimental injectable drug, targets three hormones related to weight loss.…
Eli Lilly says next-generation weight loss drug clears crucial obesity trial
The results bring Lilly one step closer to filing for approval of the injection, retatrutide, which works differently from existing injections and pills.…
STAT+: Pharmalittle: We’re reading about a Lilly obesity drug trial, statistics for an Alzheimer’s drug, and more
Eli Lilly reported that in a late-stage trial, its next-generation obesity drug led to weight loss approaching the effectiveness seen with bariatric surgery…
Eli Lilly is acquiring gene therapy biotech Engage Bio for up to $202 million
Eli Lilly's next-generation weight loss injection posted record results in obesity trial
Lilly’s new experimental shot produced 28% weight loss
Eli Lilly's New Weight-Loss Treatment Shows Promising Results - Morningstar
Comprehensive up-to-date news coverage, aggregated from sources all over the world by Google News.…
Lilly’s retatrutide shows 28.3% weight loss in phase 3 trial
STAT+: Lilly’s ‘triple-G’ drug leads to bariatric-surgery levels of weight loss in trial
A next-gen Eli Lilly obesity drug led to bariatric-surgery levels of weight loss in a study, but also saw patients dropping out because of side effects.…
Lower cost Novo, Lilly weight-loss pills draw patients from compounded drugs, doctors say
People lost up to 85 pounds on Lilly’s experimental weight loss drug, company says
The results — the most weight loss ever seen in a medication trial — put the drug’s effectiveness on par with bariatric surgery.…
Eli Lilly accuses church bishops, businessmen of fraud in Trulicity drug rebate scheme
Eli Lilly claims in a civil lawsuit that it's the victim of a $200 million plus drug rebate fraud tied to Pentecostal church bishops and businesses.…
Eli Lilly Buys Engage Biologics for Up to $202 Million - Morningstar
Comprehensive up-to-date news coverage, aggregated from sources all over the world by Google News.…
Trades of Eli Lilly shares were made on Trump’s behalf as drugmaker benefitted from his policies
Filings reveal $220m to $750m in trades on US president’s behalf in first quarter of 2026, including securities linked to largest US companies…
Eli Lilly: Novo Nordisk Was Just A Warm-Up
Eli Lilly’s obesity/diabetes outlook: Tirzepatide leads near-term, Retatrutide targets Class III, Foundayo expands maintenance—see 2030 sales & $1,300 PT.…
French Regulators Fine Novo, Lilly Over GLP-1 Campaigns
French regulators say obesity awareness campaigns may blur the line between public education and the promotion of prescription weight-loss drugs.…
STAT+: Eli Lilly tops prominent rankings on pharma R&D performance
A new set of lists ranks drug company laboratories on two criteria: innovation and invention.…
Eli Lilly Is A Buy (Technical Analysis)
Eli Lilly exhibits strong bullish technicals, with price action, momentum, and relative strength all supporting a continued uptrend. See why LLY stock is a Buy.…
US Supreme Court turns away Eli Lilly's challenge to whistleblower law - Reuters
US Supreme Court turns away Eli Lilly's challenge to whistleblower law Reuters…